Latest News and Press Releases

NEW YORK, July 27, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...

- Webinar topics will cover FDA Advisory Panel on Mylotarg, developments with other CD33 targeted therapies and update on Actimab-A - Webinar to be led by Dr. Joseph Jurcic, Director of Hematologic...

-  Webinar topics will cover FDA Advisory Panel on Mylotarg, developments with other CD33 targeted therapies and update on Actimab-A -  Webinar to be led by Dr. Joseph Jurcic, Director of Hematologic...

- Iomab-B Phase 3 SIERRA trial enrollment is accelerating as the number of clinical trial sites increase, competitive position as only induction and conditioning regimen remains unchallenged -...

- Dr. Nitya Ray joins Actinium Executive Team with 30 years of radiopharmaceutical and biologics product development, manufacturing and strategic planning experience  - Also announced is the recent...

Dr. Rajneesh Nath, a Principal Investigator and Director of the Bone Marrow Transplant and Acute Leukemia Program at Banner MD Anderson Cancer Center will discuss his perspectives on Iomab-B in...

- Mr. Seth to serve as Chief Executive Officer and Chairman of the Board of Directors - Independent Director Dr. Ajit Shetty appointed to the Company’s Corporate Governance, Audit and Compensation...

- Society of Nuclear Medicine and Molecular Imaging to be  held June 10 – 14, 2017 in Denver, Colorado  - Actinium to conduct webinar to provide an update on its Pivotal Phase 3 drug...

- Dr. Rajneesh Nath, a Principal Investigator and Director of the Bone Marrow Transplant and Acute Leukemia Program at Banner MD Anderson Cancer Center will discuss his perspectives on Iomab-B in...

- Dr. Rajneesh Nath, a Principal Investigator and Director of the Bone Marrow Transplant and Acute Leukemia Program at Banner MD Anderson Cancer Center will discuss his perspectives on Iomab-B in...